These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9331442)

  • 1. Stability of cidofovir in 0.9% sodium chloride injection for five days.
    Ennis RD; Dahl TC
    Am J Health Syst Pharm; 1997 Oct; 54(19):2204-6. PubMed ID: 9331442
    [No Abstract]   [Full Text] [Related]  

  • 2. Stability of cidofovir in 0.9% sodium chloride injection and in 5% dextrose injection.
    Yuan LC; Samuels GJ; Visor GC
    Am J Health Syst Pharm; 1996 Aug; 53(16):1939-43. PubMed ID: 8862207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced chemical stability of the intracellular prodrug, 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, relative to its parent compound, cidofovir.
    Oliyai R; Lee WA; Visor GC; Yuan LC
    Int J Pharm; 1999 Mar; 179(2):257-65. PubMed ID: 10053218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC).
    Lalezari JP; Stagg RJ; Jaffe HS; Hitchcock MJ; Drew WL
    Adv Exp Med Biol; 1996; 394():105-15. PubMed ID: 8815677
    [No Abstract]   [Full Text] [Related]  

  • 5. Compounding of topical cidofovir.
    Goldblum OM; Zabawski EJ
    Arch Dermatol; 2002 Feb; 138(2):267. PubMed ID: 11843654
    [No Abstract]   [Full Text] [Related]  

  • 6. Structure of 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; an antiviral agent.
    Symerský J; Holý A
    Acta Crystallogr C; 1991 Oct; 47 ( Pt 10)():2104-7. PubMed ID: 1804221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Manufacturing of cidofovir for intravitreal injections in cytomegalovirus retinitis].
    Mucci M
    Rev Med Suisse Romande; 1998 Sep; 118(9):819-20. PubMed ID: 9810200
    [No Abstract]   [Full Text] [Related]  

  • 8. [Fabrication of cidofovir ampules for intravitreal injections for cytomegalovirus retinitis].
    Schleppy CA; Tritten JJ
    Rev Med Suisse Romande; 1998 Mar; 118(3):263-5. PubMed ID: 9594603
    [No Abstract]   [Full Text] [Related]  

  • 9. Stability of cidofovir in extemporaneously prepared syringes.
    Hennere G; Havard L; Bonan B; Prognon P
    Am J Health Syst Pharm; 2005 Mar; 62(5):506-9. PubMed ID: 15745914
    [No Abstract]   [Full Text] [Related]  

  • 10. High-performance liquid chromatographic determination of cytosine-containing compounds by precolumn fluorescence derivatization with phenacyl bromide: application to antiviral nucleosides and nucleotides.
    Eisenberg EJ; Cundy KC
    J Chromatogr B Biomed Appl; 1996 Apr; 679(1-2):119-27. PubMed ID: 8998550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of potential anti-poxvirus agents.
    Kern ER
    Antiviral Res; 2003 Jan; 57(1-2):35-40. PubMed ID: 12615301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of in vitro flux through hairless mouse skin of cidofovir, a potent nucleotide analog.
    Aspe E; Guy RH; Lee WA; Kennedy JA; Visor GC; Ennis RD
    J Pharm Sci; 1995 Jun; 84(6):750-4. PubMed ID: 7562417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aryl ester prodrugs of cyclic HPMPC. I: Physicochemical characterization and in vitro biological stability.
    Oliyai R; Shaw JP; Sueoka-Lennen CM; Cundy KC; Arimilli MN; Jones RJ; Lee WA
    Pharm Res; 1999 Nov; 16(11):1687-93. PubMed ID: 10571273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.
    Ciesla SL; Trahan J; Wan WB; Beadle JR; Aldern KA; Painter GR; Hostetler KY
    Antiviral Res; 2003 Aug; 59(3):163-71. PubMed ID: 12927306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.
    Aldern KA; Ciesla SL; Winegarden KL; Hostetler KY
    Mol Pharmacol; 2003 Mar; 63(3):678-81. PubMed ID: 12606777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gilead issues new warnings about cidofovir nephrotoxicity.
    Am J Health Syst Pharm; 1997 Jan; 54(1):12, 15. PubMed ID: 9117780
    [No Abstract]   [Full Text] [Related]  

  • 17. Cidofovir-induced end-stage renal failure.
    Meier P; Dautheville-Guibal S; Ronco PM; Rossert J
    Nephrol Dial Transplant; 2002 Jan; 17(1):148-9. PubMed ID: 11773481
    [No Abstract]   [Full Text] [Related]  

  • 18. Stability of 0.5% cidofovir stored under various conditions for up to 6 months.
    Stiles J; Gwin W; Pogranichniy R
    Vet Ophthalmol; 2010 Jul; 13(4):275-7. PubMed ID: 20618808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cidofovir transport in the pigmented rabbit conjunctiva.
    Hosoya K; Lee VH
    Curr Eye Res; 1997 Jul; 16(7):693-7. PubMed ID: 9222087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient.
    Ibarra V; Blanco JR; Oteo JA; Rosel L
    Acta Derm Venereol; 2000; 80(4):315-6. PubMed ID: 11028878
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.